
    
      Tube feeding rates and tube feeding residual volumes will be measured and followed blinded to
      the treatment arm (methylnaltrexone vs. placebo) to evaluate if patients (who prior to study
      entry did not tolerate goal rates tube feeds) can get closer to tube feeding goal with the
      treatment arm.
    
  